A single point mutation in the rhinovirus 2B protein reduces the requirement for phosphatidylinositol 4-kinase class 3beta in viral replication by Roulin, Pascal S et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
A single point mutation in the rhinovirus 2B protein reduces the
requirement for phosphatidylinositol 4-kinase class 3beta in viral replication
Roulin, Pascal S; Murer, Luca; Greber, Urs F
Abstract: Rhinoviruses (RVs) replicate on cytoplasmic membranes derived from the Golgi apparatus.
They encode membrane-targeted proteins 2B, 2C and 3A, which control trafficking and lipid compo-
sition of the replication membrane. The virus recruits host factors for replication, such as the phos-
phatidylinositol 4 (PI4)-kinase 3beta (PI4K3b), which boosts PI4-phosphate (PI4P) levels, and drives
lipid counter-current exchange of PI4P against cholesterol at endoplasmic reticulum-Golgi membrane
contact sites through the lipid shuttling protein oxysterol binding protein (OSBP) 1. We identified a
PI4K3b-inhibitor resistant RV-A16 variant with a single point mutation in the conserved 2B protein
near the cytosolic carboxy-terminus, isoleucine 92 to threonine [I92T]. The mutation did not confer re-
sistance to cholesterol sequestering compounds or OSBP1 inhibition, suggesting invariant dependency on
the PI4P/cholesterol lipid counter-currents. In presence of PI4K3b-inhibitor, Golgi reorganization and
PI4P lipid induction occurred in RV-A16 2B[I92], but not wild-type infection. The knock-out of PI4K3b
abolished the replication of both 2B[I92T] mutant and wild-type. Doxycyclin-inducible expression of
PI4K3b in PI4K3b knock-out cells efficiently rescued the 2B[I92T] mutant, and less effectively wild-type
virus infection. Ectopic expression of 2B[I92T] or 2B was less efficient than 3A in recruiting PI4K3b to
perinuclear membranes, suggesting a supportive rather than decisive role of 2B in recruiting PI4K3b.
The data suggest that 2B tunes the recruitment of PI4K3b to the replication membrane, and allows the
virus to adapt to cells with low levels of PI4K3b, yet maintaining the PI4P/cholesterol counter-current
for establishing Golgi-derived RV replication membranes.Human rhinoviruses (RVs) are the major cause
of common cold worldwide. They cause asthmatic exacerbations and chronic obstructive pulmonary dis-
ease. Despite recent advances, the development of antivirals and vaccines has proven difficult due to
the high number and variability of RV types. The identification of critical host factors and their inter-
actions with viral proteins and membrane lipids for the establishment of viral replication is a basis for
drug development strategies. Our findings here shed new light on the interactions between nonstructural
viral membrane proteins and class III phosphatidylinositol 4 kinases from the host, and highlight the
importance of phosphatidyl-inositol 4 phosphate for RV replication.
DOI: https://doi.org/10.1128/JVI.01462-18
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-153747
Journal Article
Accepted Version
Originally published at:
Roulin, Pascal S; Murer, Luca; Greber, Urs F (2018). A single point mutation in the rhinovirus 2B
protein reduces the requirement for phosphatidylinositol 4-kinase class 3beta in viral replication. Journal
of Virology, 92(23):e01462-18.
DOI: https://doi.org/10.1128/JVI.01462-18
2
 1 
A single point mutation in the rhinovirus 2B protein 
reduces the requirement for phosphatidylinositol 4-kinase 
class 3beta in viral replication 
 
Pascal S Roulin1*, Luca Murer1*, Urs F Greber1,2 
 
1 Department of Molecular Life Sciences, University of Zurich, Switzerland 
* These authors contributed equally to this work. 
2 corresponding author: E-mail: urs.greber@imls.uzh.ch 
Telephone: +41 44 635 48 41, Fax: +41 44 635 68 17 
 
 
 
 
 
 
  
 
 
Running title: 
 
RV-A16 compensates for low levels of PI4K class 3beta  
 2 
Abstract (238 w) 
Rhinoviruses (RVs) replicate on cytoplasmic membranes derived from the Golgi 
apparatus. They encode membrane-targeted proteins 2B, 2C and 3A, which control 
trafficking and lipid composition of the replication membrane. The virus recruits host 
factors for replication, such as the phosphatidylinositol 4 (PI4)-kinase 3beta (PI4K3b), 
which boosts PI4-phosphate (PI4P) levels, and drives lipid counter-current exchange 
of PI4P against cholesterol at endoplasmic reticulum-Golgi membrane contact sites 
through the lipid shuttling protein oxysterol binding protein (OSBP) 1. We identified a 
PI4K3b-inhibitor resistant RV-A16 variant with a single point mutation in the 
conserved 2B protein near the cytosolic carboxy-terminus, isoleucine 92 to threonine 
[I92T]. The mutation did not confer resistance to cholesterol sequestering compounds 
or OSBP1 inhibition, suggesting invariant dependency on the PI4P/cholesterol lipid 
counter-currents. In presence of PI4K3b-inhibitor, Golgi reorganization and PI4P lipid 
induction occurred in RV-A16 2B[I92], but not wild-type infection. The knock-out of 
PI4K3b abolished the replication of both 2B[I92T] mutant and wild-type. Doxycyclin-
inducible expression of PI4K3b in PI4K3b knock-out cells efficiently rescued the 
2B[I92T] mutant, and less effectively wild-type virus infection. Ectopic expression of 
2B[I92T] or 2B was less efficient than 3A in recruiting PI4K3b to perinuclear 
membranes, suggesting a supportive rather than decisive role of 2B in recruiting 
PI4K3b. The data suggest that 2B tunes the recruitment of PI4K3b to the replication 
membrane, and allows the virus to adapt to cells with low levels of PI4K3b, yet 
maintaining the PI4P/cholesterol counter-current for establishing Golgi-derived RV 
replication membranes.  
 
Importance 
Human rhinoviruses (RVs) are the major cause of common cold worldwide. They 
cause asthmatic exacerbations and chronic obstructive pulmonary disease. Despite 
recent advances, the development of antivirals and vaccines has proven difficult due 
to the high number and variability of RV types. The identification of critical host 
factors and their interactions with viral proteins and membrane lipids for the 
establishment of viral replication is a basis for drug development strategies. Our 
findings here shed new light on the interactions between nonstructural viral 
membrane proteins and class III phosphatidylinositol 4 kinases from the host, and 
highlight the importance of phosphatidyl-inositol 4 phosphate for RV replication.  
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Introduction 
Human rhinoviruses (RVs) are the most frequent cause of common colds, accounting 
for about 50% of upper respiratory tract infections (1). Although rarely life threatening, 
RVs can also replicate in the lower airways where they play a critical role in causing 
exacerbations of asthma, chronic obstructive pulmonary disease and cystic fibrosis 
(2). RVs are in the genus Enterovirus of the Picornaviridae family, and classified into 
the three species, RV-A, RV-B and RV-C (3). While the recently discovered RV-C 
types use human cadherin-related family member 3 (CDHR3) as a receptor for entry 
(4), the major types of the RV-A and B species bind to intercellular adhesion 
molecule 1 (ICAM1), and the minor types to the low density lipoprotein (LDL) family 
receptors (5). Receptor binding leads to viral endocytosis and uncoating of the viral 
RNA genome (6-8).  
The replication of plus sense RNA viruses in the cytoplasm occurs in close 
association with membranes of the secretory or the endocytic pathways (reviewed in 
9, 10-12). Picornavirus infections suppress the early onset of apoptosis and execute 
viral necrosis (13, 14). They remodel cytoplasmic membranes, which involves host 
protein recruitment to membranes, synthesis and modification of lipids, and 
alterations in membrane curvature, flux and traffic. RVs remodel cytoplasmic 
membranes where viral and cellular proteins cooperate to replicate viral RNA, so 
called replication complexes (15-17). Until recently, the morphology and origin of 
enterovirus-induced membrane rearrangements remained controversial. Serial 
electron tomography at different stages of infection revealed that poliovirus (PV) and 
coxsackievirus (CV) first form convoluted branching membrane tubules, and later on 
process them into double-membrane vesicles (16, 18). Enterovirus replication 
complexes are established in close association with cis-Golgi membranes, 
suggesting that Golgi is the initial site of replication complex (RC) formation (19-22). 
As infection progresses, the Golgi apparatus is disrupted, and replication membrane 
structures grow in number and complexity in the perinuclear area, near dilated 
endoplasmic reticulum (ER) tubules. 
The membrane-targeted 2B, 2C and 3A proteins have been implicated in remodeling 
cytoplasmic membranes into replication membranes (23-25). For example, mutations 
in 2B and 3A facilitated RV-B39 adaptation to virus growth in murine cells expressing 
the intercellular adhesion molecule 1 (ICAM-1) receptor, and enabled the formation of 
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replication membranes, thereby highlighting the importance of viral membrane 
interacting proteins (26).  
The formation of the replication membranes also critically depends on host factors, 
such as phosphatidylinositol 4 (PI4)-kinase class 3b (PI4K3b) (21, 22, 27). In 
uninfected cells, PI4K3b is located at the Golgi complex through the small GTP-
binding protein Arf1 (28). It is activated by phosphorylation at Ser268, and stabilized 
by interactions with 14-3-3 proteins. Activated PI4K3b catalyzes the formation of PI4-
phosphate (PI4P) lipids, which have key roles in signaling and vesicular trafficking at 
the Golgi complex (29). PI4K3b is recruited to the replication membranes in 
enterovirus-infected cells, where it generates high levels of PI4P (21, 22). One model 
for enrichment of PI4K3b at Golgi membranes suggested that the 3A protein of CVB3 
indirectly recruits PI4K3b via the PI4K3b effector Arf1, as 3A recruits GBF1 to the 
replication membranes, activates Arf1 and thus mimics host recruitment mechanisms 
of PI4K3b (21). Another model proposed that 3A recruits PI4K3b to the replication 
membranes by direct interactions. Expression of 3A from various enteroviruses, such 
as PV, CVB3, RV-B14, in absence of other viral proteins showed that 3A co-purified 
with PI4K3b (30). Interestingly, another host protein, acyl-CoA binding domain 
containing 3 (ACBD3) also known as GCP60, co-purified with the 3A-PI4K3b 
complex and was able to bind PI4K3b independently of 3A (30). This suggests that 
ACBD3 acts as an adaptor for 3A to recruit PI4K3b. Yet, PI4K3b recruitment by 
CVB3 3A protein can also occur independently of GBF1, Arf1 or ACBD3, suggesting 
further mechanisms of lipid kinase recruitment to the RCs (31). 
Here, we identified a novel mutation in the 2B protein of RV-A16, which was sufficient 
to render virus resistant to PI4K3b inhibitors or PI4K3b knock-down. The single point 
mutation occurred in a site, which is highly conserved within species A and B 
rhinoviruses. Unlike enterovirus 3A mutants, the RV-A16 mutant retained the ability 
to use the PI4P/cholesterol lipid counter currents on the replication membranes, akin 
to native RV-A16. The mutant virus could not replicate in absence of PI4K3b but 
replicated more efficiently at limiting levels of PI4K3b, as shown by dose dependent 
doxycycline induction of ectopic PI4K3b in PI4K3b knock-oiut (KO) cells. We suggest 
that the 2B[I92T] mutant protein facilitates the recruitment of PI4K3b to the replication 
membrane.  
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Materials and Methods 
Chemicals, plasmids, antibodies, and cell lines 
PIK93 was purchased from Selleck Chemicals; BFA from LC Laboratories; MbCD, 
and 25-HC from Sigma; CAY10499 from Cayman Chemical. GSK2998533A (short 
GSK533A) was a kind gift from from S. You (GlaxoSmithKline, Infectious Disease 
R&D, North Carolina, USA); compactin from L. Rohrer (Institute of Clinical Chemistry, 
University Hospital Zurich, Switzerland); AL-9 and C23 from R. De Francesco (Istituto 
Nazionale di Genetica Molecolare, Milano, Italy). RV-A16 was used as in (32). The 
RV-A16 genomic replicon pR16 was a gift from W. Lee (Department of Pediatrics, 
School of Medicine and Public Health, University of Wisconsin, USA). The CVB3 
genomic replicons pRLuc-CB3/T7 and pRLuc-CB3/T7-3A[H57Y] were a gift from F. 
van Kuppeveld (Department of Infectious Diseases & Immunology, University of 
Utrecht, Netherland). cDNAs encoding the RV-A16 nonstructural proteins myc-2B, 
myc-3A, myc-3AB were obtained from A. Mousnier (Imperial College London), and 
expressed from the pRK5-myc plasmid (Clontech) from the CMV promoter and with 
SV40-poly adenylation signal as described (33). Mouse monoclonal (Mab) 16-7 
directed against VP2 (W.M. Lee, Department of Pediatrics, School of Medicine and 
Public Health, University of Wisconsin, USA) and Mab J2 against dsRNA (English & 
Scientific Consulting) were used as described (32), rabbit polyclonal antibody against 
VP1 (from K. Niespodziana and R. Valenta, Division of Immunopathology, University 
of Graz, Austria, 34), Mabs against GM130 and PI4K3b (BD Transduction 
Laboratories), Mab against PI4P (Echelon), Mab 1C4 against PI4K2a (S. Minogue, 
Institute of Liver and Digestive Health, University College London, UK), and Alexa 
Fluor-488 or -594 labeled secondary antibodies against mouse or rabbit IgG or IgM 
(Invitrogen). HeLa cervical carcinoma cells strain Ohio (HeLa, from L. Kaiser, Central 
Laboratory of Virology, University Hospital Geneva, Switzerland) were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and 1% L-glutamine, called full medium. 
Generation of PIK93-resistant viruses 
HeLa cells were cultured in 96-well plates overnight at 37°C in full medium, and 
infected with wild-type (WT) RV-A16. PIK93-resistant viruses were obtained by serial 
passages in presence of increasing concentrations of PIK93 for 6 days at 33.5°C. 
Supernatants from cultures with full CPE at highest concentration of drug were 
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passaged until full CPE was observed at a PIK93 concentration that did not allow 
replication of the initial inoculum (for example, WT virus at 1 µM PIK93). Resistant 
virus pools were subjected to plaque purification by culturing HeLa cells in 6-well 
plates at 37°C in full medium overnight, inoculated with the PIK93-resistant virus pool 
in 10-fold dilution series in full medium complemented with 1 µM PIK93 at 33.5°C. At 
5 h post-infection, the medium was discarded and replaced by fresh full medium 
complemented with 0.6% agarose (Affymetrix), 1% penicillin/streptomycin solution 
(Gibco), and 1 µM PIK93. The 6-well plates were incubated for 6 days at 33.5°C. 
Single plaques were identified and collected for further amplification in HeLa cells on 
6-well plates for 2 days at 33.5°C. Total RNA was extracted using TRI reagent, and 
cDNAs obtained by reverse transcription using SuperScript III according to the 
manufacturer’s instructions. PCR fragments covering the nonstructural region of RV-
A16 were amplified using Pfu polymerase (Promega) and analyzed by Sanger DNA 
sequencing. 
Site-directed mutagenesis 
The site-specific substitution I92T was introduced into the genomic replicon clone of 
RV-A16 by PCR overlap extension. The first PCR reaction using Pfu polymerase 
generated two fragments with overlapping ends. The sense primer (5’-AAA GCT TCC 
TAG GCA GAT CG-3’) and the anti-sense primer harboring the I92T mutation (5’-
CTG ATT CTT TGT GTG TAT AAG TTA ATT-3’) were used to amplify the first 
fragment with the genomic replicon pR16 as template. The second fragment was 
generated with the same template, the anti-sense primer (5’-TTC ACT GCC CGG 
GTC AGC AT-3’) and the sense primer harboring the I92T mutation (5’- CAA TTA 
ACT TAT ACA CAC AAA GAA TCA-3’). The PCR amplification occurred as follows: 
pre-heating at 94°C for 2 min, denaturation at 94°C for 30 sec, annealing at 55°C for 
30 sec, and extension at 72°C for 2 min. The cycle was conducted 25 times, followed 
by incubation at 72°C for 5 min. The amplified PCR fragments were purified and 
extracted by electrophoresis from a 1% agarose gel. The second PCR round 
involved the two overlapping fragments as templates and the two primers located at 
both ends. The final fragment was amplified with Pfu polymerase as follows: pre-
heating at 94°C for 2 min, denaturation at 94°C for 30 sec, annealing at 55°C for 30 
sec, and extension at 72°C for 4 min. The cycle was conducted 25 times, followed by 
incubation at 72°C for 5 min. The final amplified PCR fragment harboring the I92T 
mutation was gel purified, sequentially digested with AvrII and XmaI restriction 
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enzymes (Promega), and reintroduced into the original pR16 plasmid. Presence of 
the mutation in the newly generated genomic replicon pR16 2B[I92T] was confirmed 
by sequencing. 
In vitro RNA transcription and crude virus stock production 
The plasmids pR16 WT and pR16 2B[I92T] were linearized with SacI (Promega), 
extracted with phenol:chloroform, and in vitro transcribed using T7 RNA polymerase 
(Fermentas) according to manufacturer’s instructions at 37°C for 2 h, DNAse and 
RNA treated, and extracted by phenol:chloroform. HeLa cells were cultured in 24-well 
plates overnight at 37°C in full medium, transfected with 250 ng of purified RNA using 
the TransIT-mRNA transfection kit (Mirus) according to manufacturer’s instructions. 
When cultures exhibited extensive CPE after 2 days of incubation at 37°C, virus was 
harvested from cells and supernatant, freeze/thawed three times, and centrifuged at 
5000 x g for 5 min. Supernatants were collected, and titrated in a TCID50 assay. 
Equal MOIs from pR16 WT and pR16 2B[I92T] stocks were used in infection assays. 
Interference and high-throughput infection 
Small interfering RNAs (siRNAs) were reverse transfected to HeLa cells in 96-well 
plates using serum-free Opti-MEM (Invitrogen) and Lipofectamine RNAiMAX 
(Invitrogen) (20 nM, 37°C, 72 h), and inoculated with crude virus stocks (MOI 20) at 
33.5°C for 8 h. For chemical interference assay, HeLa cells were treated with drugs 
at 1 h pi, infected with crude virus stocks (MOI 20) at 33.5°C for 8 h, fixed, stained 
with Mab J2, and scored for infection. Images were acquired with an ImageXpress 
Micro microscope (Molecular Devices) in automated mode, using a CoolSNAP HQ 
12bit gray scale camera (Roper Scientific) and 10x/NA 0.5 objective (Nikon), and 
analyzed with a custom written script in Matlab (MathWorks, Inc. Natick, MA, USA) 
(35-37), or in R. Infection indexes were calculated as the fraction of infected cells per 
total cell number, and plotted with GraphPad Prism software (GraphPad), or with R. 
Immunofluorescence and confocal microscopy 
HeLa cells on coverslips were treated with PIK93 and infected with crude virus stocks 
at 33.5°C for 8 h. Alternatively, HeLa cells were transfected with plasmid DNA using 
Lipofectamine 2000 (Invitrogen) for 24 h. For PI4P staining, plasma membrane and 
cytoplasmic PI4P pools were stained, and quantitated by expanding the DAPI-mask 
as described (22, 38). Other immunofluorescence staining was done with cells fixed 
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with 4% PFA and permeabilized with 0.2% Triton X-100, blocked for 1 h in PBS 
supplemented with 1% bovine serum albumin (BSA), followed by primary antibodies 
in blocking buffer overnight at 4°C. Alexa Fluor-488 or -594 secondary antibodies 
were used in blocking buffer for 1 h. Coverslips were mounted in mounting medium 
(Dako) and analyzed with an upright Leica TCS SP8 scanning laser confocal 
microscope with an HCX PL APO 63×/1.4 oil immersion objective. Images were 
acquired using LAS AF software (Leica), processed with ImageJ (National Institutes 
of Health), and quantitated as described earlier (22). Quantification of PI4P signal in 
single cells was carried out by maximal projection of eight z-stacked images of 2 µm 
width for each channel. An outline extending 10 pixels from the nuclear periphery 
based on DAPI staining was used to define a perinuclear area for PIP4 intensity 
quantification. The average score normalized by area was plotted as relative fold 
change. 
CRISPR/Cas9 knock-out and inducible expression of PI4K3b 
Knock-out HeLa-OHIO cell lines were generated with a modified version of the 
lentiCRISPRv2 one vector system described in (39). The Cas9 cassette was 
exchanged with the high-fidelity Cas9 variant by using the XbaI and BamHI restriction 
sites (40). For tetracycline inducibility, the promotor region was extended at the 
EcoRI, XbaI and the XhoI sites by the thyroid hormone response element (TRE), the 
TetR on pCW57.1 (Addgene 41393) and the EF1a from Lenti-eCas9 (Addgene 
52962). The sequences introduced into the plasmid as templates for the gRNA were 
5’-GCACGGCAGTTACACCACTG-3’ for the PI4K3b KO, and 5’-
GGATCCTGAGTTCGAGGCGG-3’ for the PI4K2a KO. Clonal knock-out cell lines 
were raised by limiting dilution of parental polyclonal cells. Individual clones were 
analyzed for expression of PI4K2a or PI4K3b by Western blotting.  
For the generation of a cell line expressing tetracycline-inducible PI4K3b, full-length 
complementary DNA (cDNA) of Homo sapiens PI4K3b (accession no. 
XM_005245264.3) was cloned into the lentiviral expression vector pLVX-IRES-Puro 
(Clontech) using the XhoI and the NotI restriction sites. Lentiviral particles were 
produced by co-transfecting HEK-293T cells with pCMVR8.91-Gag-Pol and pVSV-G 
(Clontech) and the lentiviral expression constructs. HeLa-OHIO or HeLa-OHIO 
PI4K3b KO cells were transduced with the lentiviral particles and cultured in 5 µg/ml 
puromycin (Invitrogen). Tetracycline-inducible PI4K3b was expressed by doxycycline 
at indicated concentrations.   
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Results 
PIK93-resistant RV-A16 is mutated in 2B  
PI4K3b is a key host factor for replication of enteroviruses, and chemical inhibitors of 
PI4K3b block enterovirus infections (12). Mutants of PV, CVB3 and RV-B14 that had 
been found to be resistant to PI4K3b inhibitors all carried mutations in 3A. However, 
no RV-A mutants were reported (41-44). RV-A16 is highly sensitive to PIK93, which 
binds to the ATP binding site of PI4K3b (45). PIK93 has a half effective concentration 
(EC50) of 250 nM (22). We investigated whether PIK93-resistant mutants would also 
occur in the 3A protein of RV-A16. RV-A16 was serially cultured in presence of 
increasing concentrations of PIK93. After 11 passages, a PIK93-selected RV-A16 
pool emerged that grew in presence of 1 µM PIK93 (not shown). When this pool of 
mutants was inoculated to fresh cells at MOI 20 for 8 h, it gave rise to infection in 
presence of up to 4 µM PIK93, whereas RV-A16 WT was strongly inhibited by low 
concentrations of PIK93 (Fig. 1A). Inoculation with different amounts of virus at 1 µM 
PIK93 gave rise to dose-dependent infections, in which the PIK93-selected variant 
replicated better than the WT at comparable MOI (Fig. 1B). This shows that we 
selected RV-A16 variants resistant to PIK93. 
Viruses from the pool were plaque purified in presence of 1 µM PIK93 and 12 
independent clones were picked for genotyping. Sequencing of genomic segments 
encompassing the nonstructural proteins 2B, 2C, 3A, 3B, 3C, and 3D showed that all 
12 clones had a single point mutation in the membrane-associated protein 2B at 
position isoleucine 92 to threonine [I92T]. With the exception of a silent mutation in 
the 3C protein, no other mutations were observed. 2B is a small protein of about 100 
amino acids and contains two hydrophobic domains required for membrane binding 
and correct localization in ER and Golgi membranes (46). The [I92T] mutation in the 
cytoplasmic C-terminal tail of 2B is located in a highly conserved region, indicated by 
amino acid sequence alignment of 99 RV-A and RV-B types (Fig. 1C, D). The [I92T] 
mutation facing the cytosol alters the side chain properties from a hydrophobic (I) to a 
polar (T) amino acid, and could be in direct contact with a host or viral protein to 
compensate for the reduction in PI4P.  
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The 2B[I92T] mutant is resistant to PI4K3b inhibitors and depends on 
OSBP1 
To test if the [I92T] mutation in 2B was necessary and sufficient to confer resistance 
to PI4K3b inhibitors, we introduced the 2B[I92T] mutation to a plasmid encoding an 
infectious full-length RV-A16 WT genome (pR16.11), and generated crude virus 
stocks from RV-A16 WT and RV-A16 2B[I92T] replicons. The PI4K3b inhibitors 
PIK93 and GSK533A reduce RV-A16 replication at EC50 of 250 nM and 40 nM, 
respectively (22). Both compounds were less effective against RV-A16 2B[I92T], as 
indicated by immunofluorescence infection assays using anti-dsRNA antibodies (Fig. 
2A). Notably, the Arf-GEF inhibitor brefeldin A (BFA) was similarly effective against 
both WT and 2B[I92T], validating the assay system used here. The calculated EC50 
of PIK93 for RV-A16 2B[I92T] was 1.8 µM, about 3 fold higher compared to RV-A16 
WT, which was previously shown to be 0.6 µM (22). Similarly, the 2B[I92T] mutant 
replicated better than RV-A16 WT in the presence of GSK533A with 2.3 fold higher 
EC50 than WT (73.9 nM and 32.5 nM, respectively). The reduced sensitivity of RV-
A16 2B[I92T] to PIK93 and GS533A was in the same range as for a PI4K3b resistant 
CVB3 mutant 3A[H57Y], reported earlier (44), which was as sensitive to BFA as 
native CVB3 (Fig. 2B). The data show that the 2B[I92T] mutation conferred 
resistance to PI4K3b inhibitors independent of the chemical mode of inhibition, 
suggesting a role of the 2B protein in the recruitment or activation of PI4K3b for RV-
A16 replication.  
In addition to PI4K3b, enterovirus replication critically depends on PI4P/cholesterol 
counter-currents at the replication membranes, and the lipid exchange protein 
OSBP1 (22, 47, 48). The RV-A16 2B[I92T] mutant was as dependent on OSBP1 and 
cholesterol as native RV-A16, indicated by sensitivity to the OSBP1 inhibitor 25-
hydroxycholesterol (25-HC), and the cholesterol esterase inhibitor CAY10499, with 
EC50 values of 0.86 µM, 2.16 µM for RV-A16 2B[I92T], and 0.97 µM, 2.62 µM for RV-
A16 WT, respectively (Fig. 3A, B). 25-HC binds to the cholesterol binding pocket of 
OSBP1 with higher affinity than cholesterol, and blocks the lipid exchange activity of 
OSBP1 (49). This contrasts the CVB3 3A[H57Y] mutant, which was insensitive to 
both the 25-HC and CAY10499, unlike CVB3 WT, which was sensitive to high 
concentrations of 25-HC (Fig. 3C, D). The dependency of RV-A16 2B[I92T] on 
cholesterol was further supported by the finding that it was at least as sensitive to the 
cholesterol sequestering compound methyl-β-cyclodextrin (MbCD) as RV-A16, with 
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EC50 values of 2.16 µM, and 2.62 µM, respectively (Fig. 3E). Both RVs were 
insensitive to the cholesterol synthesis inhibitor compactin (Fig. 3F) (50), as reported 
earlier for RV-A16 (22). The data thus far show that RV-A16 2B[I92T] depends on 
cholesterol, cholesterol esterases and the PI4P/cholesterol exchange protein 
OSBP1. 
The RV-A16 2B[I92T] mutant requires other PI4Ks than PI4K3b 
To further explore how the 2B[I92T] mutant uses the PI4P/cholesterol lipid counter 
currents, we transfected cells by siRNA targeting OSBP1 and PI4K3b, inoculated 
virus at MOI 20, and analyzed infections by immunofluorescence against dsRNA and 
high throughput-automated microscopy. As expected, RV-A16 2B[I92T] was nearly 
as sensitive to OSBP1 knock-down as RV-A16 WT, and much less sensitive to 
PI4K3b knock-down (Fig. 4A). This suggested that the virus can take advantage of 
PI4K3b if this enzyme is available. The selective PI4K3a inhibitor C23 neither 
inhibited RV-A16 WT nor RV-A16 2B[I92T] (Fig. 4B). C23 is 100-fold more selective 
against PI4K3a than PI4K3b, with IC50 values of 16 nM and 1.6 µM, respectively (51), 
which makes it unlikely that PI4K3a is used for RV-A16 2B[I92T] infection.  
RV-A16 2B[I92T] disperses the Golgi apparatus in presence of PIK93 
To further analyze how 2B[I92T] replicates and drives the PI4P/cholesterol counter-
current we investigated the integrity of the cis-Golgi by GM130 staining. As expected 
from previous results with RV-A16 (22), both RV-A16 WT and 2B[I92T] infections 
lead to dispersion of the Golgi apparatus in absence of PIK93 (Fig. 5). RV-A16 
2B[I92T] but not WT dispersed the Golgi membrane in presence of PIK93 (Fig. 5). 
2B[I92T] infection increased the overall cytoplasmic levels of PI4P even in presence 
of PIK93, indicated by anti-PI4P antibody staining (Fig. 6A). In the absence of PIK93, 
the perinuclear PI4P levels significantly increased 2.8 and 2.67-fold in RV-A16 WT 
and 2B[I92T] infected cells, respectively, and 2.3-fold in 2B[I92T] infected cells in 
presence of PIK93 (Fig. 6B). PIK93 strongly blocked perinuclear PI4P increase in WT 
infected cells.  
To explore if class III PI4Ks were involved in the increase of PI4P in 2B[I92T] infected 
cells, we immuno-stained cells with antibodies against PI4K3b. Infected cells were 
scored by antibodies against the capsid proteins VP1. PI4K3b was enhanced in the 
perinuclear area by both WT and 2B[I92T] virus infections (Fig. 6C, D). In control 
cells, the recruitment of PI4K3b was higher in cells infected with the 2B[I92T] mutant 
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than WT, that is 2.44 and 1.86-fold respectively. PIK93 significantly abrogated the 
enrichment of PI4K3b to perinuclear areas of WT, but not 2B[I92T] mutant infected 
cells, where the perinuclear levels were 2.11-fold higher than in uninfected cells. This 
suggests that the 2B[I92T] mutation enhances the recruitment of PI4K3b at the 
replication membranes, even in presence of PIK93.  
RV-A16 2B[I92T] replicates at low levels of PI4K3b 
To scrutinize if the 2B[I92T] mutant takes advantage of very low levels of PI4K3b, we 
engineered a cell line for doxycycline (Dox)-inducible expression of PI4K3b in the 
background of PI4K3b KO HeLa-OHIO cells. The PI4K3b knock-out (KO) cells were 
completely resistant to WT and the 2B[I92T] mutant virus, while PI4K2a KO cells 
were fully susceptible to both viruses (Fig. 7A). Dox induced PI4K3b in a dose 
dependent manner (Fig. 7B). Notably, the induced PI4K3b was running slightly faster 
in the SDS-PAGE than the endogenous HeLa cell protein. The cDNA encoding the 
induced PI4K3b was missing the exon encoding amino acids 304 – 318 accounting 
for about 1.5 kDa. Since the difference between the endogenous and the induced 
PI4K3b is about 10 kDa, and a faint upper band running at the position of the 
endogenous protein is present in the induced cells, we suspect that the two bands 
differ in the levels of post-translational modifications, such as sumoylation, 
phosphorylation or ubiquitination. Regardless, the expression of PI4K3b enhanced 
the titers of WT by 1.67 logs, and the 2B[I92T] mutant by 2.33 logs (Fig. 7C). The 
enhancement of infection was consistently larger for the 2B[I92T] mutant than the 
WT, as indicated by measuring VP2 production at different dosage of Dox at both 8 
and 16 h pi (Fig. 7D). These results indicate that the 2B[I92T] mutant replicates better 
at low PI4K3b levels than WT.  
The RV-A16 3A protein recruits PI4K3b  
We examined if one of the nonstructural viral proteins recruits the kinase responsible 
for PI4P generation. HeLa cells were transfected with myc-tagged viral protein 2B 
WT, 2B[I92T], 3A or 3AB, and analyzed by immuno-fluorescence staining against 
PI4P, and PI4K3b. None of the viral proteins except 3AB enhanced the levels of PI4P 
(Fig. 8A), in agreement with results from other enteroviruses (48). Expression of 3A 
protein was sufficient to recruit PI4K3b at perinuclear sites, while 3AB was less 
efficient in doing so (Fig. 8B). Notably, neither 2B WT nor 2B[I92T] proteins had an 
apparent effect on intracellular PI4P levels or PI4K3b recruitment. This suggests that 
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the 3A protein is the predominant recruitment factor for PI4K3b to perinuclear 
membranes, and the 3AB precursor an enhancer of PI4P levels, perhaps by 
activating PI4K activity. In sum, RV-A16 2B[I92T] alone is not able to enhance PI4P 
levels or to recruit PI4K3b to perinuclear membranes. This excludes the 2B protein 
as a stand-alone recruiting factor for PI4K3b, but rather suggests a supporting or 
stabilizing role of 2B in the recruitment of PI4K3b by 3A and 3AB.  
 
Discussion 
The best studied picornaviruses are enteroviruses. Enteroviruses comprise 12 
genera Enterovirus A-J and Rhinovirus A, B, C, and include well known agents, such 
as PV, coxsackieviruses and human rhinoviruses. These viruses all induce the 
formation of single membrane clusters in proximity to Golgi and ER within just a few 
hours of infection. The replication membranes grow in size, complexity and volume 
as infection progresses, and eventually become double membrane structures. In 
case of PV and members of the alphavirus-like superfamily, such as bromovirus, this 
involves changes in fatty acid metabolism, fatty acid import and phospholipid 
synthesis, including phosphatidyl choline (PC) (52, 53). Another key lipid for 
enterovirus replication membranes is cholesterol. While de novo cholesterol 
synthesis is not required, exogenous cholesterol from receptor-mediated endocytosis 
or de-esterification of cholesterol-esters from lipid droplets is essential for enterovirus 
replication (for review, see 12). Free cholesterol is delivered to the replication 
membrane by OSBP1 and related proteins at membrane contact sites (22, 54, 55). 
This occurs by a lipid counter current flux exchanging PI4P and cholesterol, and is 
driven by the formation of PI4P through PI4Ks (28, 56). For replication of 
enteroviruses, including PV, CVB3, and RV-A and -B, the Golgi-associated PI4K3b is 
of key importance, although RV-A1A and A16 can also use PI4K2a and PI4K3a, as 
suggested by RNA interference (21, 22, 57). Notably, however, the Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 mediated KO of 
PI4K2a had no effects on RV-A16 infection (see Fig. 7A). These data highlight the 
complexity of virus-tuned lipid modulation.  
How PI4Ks are recruited to replication membranes is poorly understood. For 
enteroviruses, it was initially suggested that PI4K3b is recruited by 3A protein, either 
indirectly via GBF1 and Arf1, or directly using ACDB3 as an adaptor (reviewed in 58). 
 14 
Yet, none of these options proved to be conclusive. Instead, the expression of CVB3 
3A protein alone was sufficient to recruit PI4K3b and generate high level of PI4P 
lipids, even in GBF1, Arf1 or ACDB3 depleted cells (21, 31). A recent study 
suggested that the CVB3 mutant 3A[H57Y] can replicate in presence of PI4K3b 
inhibitors and without apparent dedicated replication membranes on Golgi 
membranes (59). Based on our results we speculate that this mutant grows in 
presence of low concentrations of active PI4K3b, perhaps akin to the 2B[I92T] 
mutant.  
We show that the 2B[I92T] mutant confers resistance to PI4K3b inhibitors. Isoleucine 
92 is highly conserved among RV-A and RV-B species and located near the cytosolic 
carboxy-terminus of 2B. 2B comprises about 100 amino acids, forms membrane 
pores by virtue of two hydrophobic domains and oligomerization, localizes to Golgi 
membranes, and inhibits protein trafficking (46, 60, 61). Similar to 3A, expression of 
RV-A16 2B protein alone suffices to block protein secretion, although RV-A16 
infection did not apparently inhibit the release of a reporter protein Gaussia luciferase 
up to 7 h pi, suggesting that virus infection does not block the entire secretory 
pathway (33).  
Remarkably, the RV-A16 2B[I92T] disrupted the Golgi, recruited PI4K3b, and 
enriched PI4P on replication membranes in the presence of PI4K3b inhibitors. RV-
A16 2B[I92T] remained sensitive to other inhibitors of the PI4P/cholesterol counter-
current flux. Remarkably, PI4K3b localizes close to OSBP1, and thereby allows the 
steady exchange of lipids between the ER and the Golgi stacks, depending on the 
OSPB1 anchoring protein VAP (62). VAP was also important for RV replication, as 
shown by RNA interference and the expression of dominant-negative OSPB1 
mutants lacking the PI4P binding domain but retaining the VAP binding domain FFAT 
(22). PI4K2a which does not locate to the proximity of OSBP1 leads to oscillating flux 
of PI4P (62), and this correlates with PI4K2a being unable to support RV-A16 
replication (see Fig. 7A). 
The phenotype of RV-A16 2B[I92T] appears to be different from the previously 
reported 3A mutants, which to replicate in a PI4K3b-independent manner when 
PI4K3b activity is impaired (41-44). This suggests that the A16 2B protein has a 
different function(s) than 3A protein in the generation of replication membranes. In 
support of this notion, the expression of 3A but not 2B protein alone recruited 
PI4K3b, and the precursor 3AB increased PI4P levels in transfected cells. This is 
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different from the coxsackievirus (CV) 3A protein, which recruited PI4K3b and 
increased PI4P (44). Further, the replication of the CVB3 3A[H57Y] mutant in 
presence of PI4K inhibitors no longer depended on PI4K3b, or other PI4K isoforms, 
did not disrupt the Golgi membranes, and did not increase the PI4P levels (44).  
In contrast, the RV-A16 2B[I92T] mutant replicated at lower levels of PI4K3b than 
WT, as indicated by tunable expression of PI4K3b, and two different chemicals 
targeting the ATP binding site of PI4K3b. It was sensitive to RNA interference against 
PI4K3b, suggesting either a lower requirement, or a non-enzymatic function of 
PI4K3b for RV-A16 2B[I92T] replication. Notably, PI4K3b recruits small GTPases 
independent of its catalytic activity, and fine tunes vesicular transport (45). 
Consistently, the complete knock-out of PI4K3b by CRISPR/Cas9 abrogated both 
RV-A16 WT and 2B[I92T] infections, which were however insensitive to PI4K2a 
knock-out. This strengthens the notion, that the 2B[I92T] reduces, but does not 
eliminate the requirement for PI4K3b. Low residual functionality of PI4K3b resulting 
from incomplete inhibition by a compound, or siRNA knockdown would therefore be 
sufficient for the replication of RV-A16 2B[I92T], but not WT.  
It is possible that the transmembrane domains of 2B and 3A or 3AB interact, as 
suggested for the poliovirus proteins by yeast-two-hybrid experiments (63). We 
speculate that the respiratory RV-A16 uses the 2B protein together with 3A to recruit 
PI4K3b. This is based on the notion that there are no RV-A types known to have 
mutations in 3A, which would make them resistant to PI4K3b inhibitors. Since the N-
terminus of 3A from RV-A types lacks 6 amino acids, which are present in RV-B 
types, we conjecture that RV-A types require an additional viral protein for effective 
recruitment of PI4Ks to the replication membrane. We further suggest that CVB or 
RV-B can drive the lipid currents that are crucial for establishing the replication 
membrane by taking advantage of another asymmetry than PI4P lipids. Such 
asymmetrically distributed lipids could comprise PC. Notably, the phosphatidyl 
inositol transfer protein b (PITPb) shuttles phosphatidyl inositol (PI) in exchange to 
PC between the ER and Golgi membranes, and is required for RV-A1A and RV-A16 
replication (22). Intriguingly, PC with short acyl chain lengths are enriched in PV 
infected cells (52), giving rise to the possibility that PC lipids are involved in tuning 
the composition of the replication membrane.  
In summary, our results show that despite the great plasticity of the host lipid 
landscape and the readily mutating nonstructural proteins of picornaviruses the cells 
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provides key metabolic circuits for establishing picornavirus replication membranes. 
One of these circuits is the PI4P/cholesterol counter-current flux. Host components 
that regulate this flux are surgically targeted by at least two nonstructural membrane 
proteins of RV-A16, 2B and 3A to drive viral replication on cytoplasmic membranes.  
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Figure Legends 
FIG 1: Identification of a PIK93-resistant RV-A16 2B[I92T] mutant 
(A) HeLa cells were infected with RV-A16 WT (white bars) or RV-A16 PIK93-resistant 
virus pool (black bars) at a MOI 20 for 8 h. Cells were treated with PIK93 at indicated 
concentrations, and infection efficiencies were analyzed by high-throughput 
immunofluorescence microscopy using anti-VP2 antibodies. The ratio of infected 
cells was calculated and normalized to control infection without drug. Values 
represent the means ± SD, n=2. 
(B) HeLa cells were infected with RV-A16 WT (white bars) or RV-A16 PIK93-resistant 
pool (black bars) at indicated MOI for 8 h, in presence of 1 µM PIK93. Experiment 
was analyzed as in panel A. Values represent means ± SD, n=2. 
(C) Pairwise alignment of 2B proteins from RV-A1 (formerly known as RV-A1a or RV-
A1b), -A2, -A16, -B14, and -B37, and CVB3 by ClustalW using a Blosum62 similarity 
matrix. The hydrophobic regions 1 and 2 are present in all proteins and separated by 
a five amino acid spacer. Note that the isoleucine located at the 92 position (I92) is 
near the C-terminal end.  
(D) ClustalW alignement of 2B amino acid sequences from 99 different RV types (74 
RV-A and 25 RV-B; 11 minor RV and 88 major RV) using a Blosum62 similarity 
matrix. Prevalence of the amino acids isoleucine (I) and valine (V) at position 92 or 
equivalent were depicted by WebLogo from the aligned sequences. In addition, the 
prevalence of the amino acid threonine (T) at position 92 or equivalent was depicted 
for the 12 clones selected in the PIK93-selected mutant pool. 
 
FIG 2: Resistance of the RV-A16 2B[I92T] mutant to PI4K3b inhibitors 
(A) HeLa cells were infected with RV-A16 WT (white bars) or RV-A16 2B[I92T] (black 
bars) at a MOI of 20 for 8h, in presence or absence or brefeldin A (BFA), PIK93 or 
GSK533A. Data were analyzed as described in Fig. 1, except that anti-dsRNA 
staining was used here, and normalized to the DMSO control. Values represent 
means ± SD, n=2. 
(B) Same experiment as in panel (A), except that cells were infected with CVB3 WT 
(white bars) or CVB3 3A[H57Y] (black bars). 
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FIG 3: Similar susceptibility of RV-A16 2B[I92T] and WT to inhibitors 
blocking PI4P/cholesterol counter-currents 
HeLa cells were infected with RV-A16 WT (white bars) or RV-A16 2B[I92T] (black 
bars) at a MOI of 20 for 8 h (panels A, B, E, F), or with CVB3 WT or the 3A[H57Y] 
mutant (C, D), in presence or absence of brefeldin A (BFA), the OSBP inhibitor 25-
HC (A, C), the cholesterol esterase inhibitor CAY10499 (B, D), the cholesterol 
depleting drug MbCD (E), or the cholesterol synthesis inhibitor compactin (F). 
Infections were analyzed as described in figure 1. Values represent means ± SD, 
n=2. 
 
FIG 4: Dependency of RV-A16 2B[I92T] on PI4Ks 
(A) HeLa cells were transfected with siRNA against OSBP1, PI4K3b, or the negative 
control siRNA (all star, Qiagen). Three days post-transfection, cells were infected 
with RV-A16 WT (white bars) or RV-A16 2B[I92T] (black bars) at a MOI 20 for 8 h, 
and analyzed for fraction of infected cells. Values represent means ± SD, n=2. 
Western blots against OSBP1 and PI4K3b demonstrate the efficiency of protein 
knock-down by the corresponding siRNAs.  
(B) HeLa cells were infected with RV-A16 WT (white bars) or RV-A16 2B[I92T] (black 
bars) were treated with DMSO, brefeldin A (BFA) or the PI4K3a inhibitor C23 (B), 
and analyzed as described in figure 1. Values represent means ± SD, n=2. 
 
FIG. 5: Golgi disruption in RV-A16_2B[I92T] and WT infection 
HeLa cells treated with DMSO or PIK93 (1 µM) were infected with RV-A16 WT or 
2B[I92T] at MOI 20 for 8 h, and stained for viral protein VP1 (green) and GM130 
(red). Nuclei stained with DAPI are in blue. Single z-planes from confocal imaging are 
shown. Scale bar is 10 µm. 
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FIG 6: RV-A16_2B[I92T] mutant enhances PI4P and recruits PI4P2a and 
PI4K3b 
HeLa cells were treated with DMSO or PIK93 (1 µM), infected with RV-A16 WT or 
2B[I92T] at MOI 20 for 8 h, stained for viral protein VP1 and PI4P (A), or PI4K3b (C), 
and nuclei were stained with DAPI. Images show single z-planes. Quantifications of 
perinuclear PI4P (B) and PI4K3b (D) show relative signal intensities per area from 
total projections with number of cells analyzed (n) and mean values and SD. Scale 
bar: 10 µm. 
 
FIG. 7: RV-A16 2B[I92T] replicates at low levels of PI4K3b 
(A) HeLa-OHIO cells were subjected to CRISPR/Cas9 knock-out with guide RNAs 
(gRNAs) targeting PI4K2a and PI4K3b. Knock-out was verified by Western blotting. 
The indicated cell lines were infected at a MOI of 20 for 8 h, and analyzed for 
infected cells. Values representing fraction of infected cells represent means ± SD, 
n=3. 
(B) HeLa-OHIO PI3K3b KO cells were stably transfected with a doxycycline inducible 
PI4K3b cassette. Expression of PI4K3b was induced by different dosage of 
doxycycline for 24 h, and PI4K3b levels analyzed by Western blotting.  
(C) Cells were infected with RV-A16 WT or RV-A16 2B[I92T] (MOI 20) in presence or 
absence of doxycycline. Progeny virus was harvested at 16 h pi, and titrated on fresh 
HeLa-OHIO cells.  
(D) Cells were infected at MOI 20 in presence or absence of doxycycline and 
infection was assessed after 8 h and 16 h respectively. Values represent means ± 
SD, n=2-3. 
 
FIG 8: PI4K 3b recruitment by the RV-A16 3A protein 
HeLa cells were transfected with plasmid DNA encoding myc-tagged 2B, 2B[I92T], 
3A and 3AB, stained with anti-myc antibodies (green), and with antibodies against 
PI4P (A) or PI4K3b (B). Nuclei were stained with DAPI. Representative single section 
confocal images are shown. Scale bar: 10 µm. 
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